ENTRY       D09321                      Drug
NAME        Obinutuzumab (USAN/INN);
            Obinutuzumab (genetical recombination) (JAN);
            Gazyva (TN)
PRODUCT     GAZYVA (Genentech)
FORMULA     C6512H10060N1712O2020S44
EXACT_MASS  145972.4812
MOL_WEIGHT  146062.6732
REMARK      Therapeutic category: 4291
            ATC code: L01FA03
            Product: D09321<JP/US>
EFFICACY    Antineoplastic, Anti-CD20 antibody
  DISEASE   Chronic lymphocytic leukemia [DS:H00005]
            Follicular lymphoma [DS:H01613]
  TYPE      Monoclonal antibody
TARGET      CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(931)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FA CD20 (Clusters of Differentiation 20) inhibitors
                 L01FA03 Obinutuzumab
                  D09321  Obinutuzumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Obinutuzumab
                D09321  Obinutuzumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09321  Obinutuzumab (USAN/INN); Obinutuzumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD20
                 D09321  Obinutuzumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09321
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09321
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09321
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09321
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09321
DBLINKS     CAS: 949142-50-1
            PubChem: 96026001
///
